发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Inhaler device selection for people with asthma or chronic obstructive pulmonary disease. 为哮喘或慢性阻塞性肺病患者选择吸入器。
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.046
Deborah Rigby
{"title":"Inhaler device selection for people with asthma or chronic obstructive pulmonary disease.","authors":"Deborah Rigby","doi":"10.18773/austprescr.2024.046","DOIUrl":"https://doi.org/10.18773/austprescr.2024.046","url":null,"abstract":"<p><p>There are many types of inhaler device, each with its own characteristics, benefits and limitations. Inhaler device selection should be individualised. Assessment of the patient's inspiratory flow, dexterity, coordination and preferences can help guide selection of a device that the patient can and will use effectively. For patients who require multiple inhaled drugs, prescribing combination inhalers and avoiding the use of more than one type of inhaler device can reduce errors in inhaler technique and improve adherence. Inhaler technique and adherence should be regularly reviewed. Environmental impact of inhalers can be reduced by optimising symptom control to minimise the need for short-acting beta<sub>2</sub> agonists, and choosing inhalers with a low carbon footprint.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"140-147"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valediction: Ruth Sutherland. 致辞露丝-萨瑟兰
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.043
{"title":"Valediction: Ruth Sutherland.","authors":"","doi":"10.18773/austprescr.2024.043","DOIUrl":"https://doi.org/10.18773/austprescr.2024.043","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"156"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis. 阿伐潘治疗抗中性粒细胞胞浆抗体相关性血管炎。
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.038
{"title":"Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis.","authors":"","doi":"10.18773/austprescr.2024.038","DOIUrl":"https://doi.org/10.18773/austprescr.2024.038","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"158-159"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fezolinetant for moderate to severe vasomotor symptoms associated with menopause. Fezolinetant 用于治疗与更年期有关的中度至重度血管运动症状。
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.042
{"title":"Fezolinetant for moderate to severe vasomotor symptoms associated with menopause.","authors":"","doi":"10.18773/austprescr.2024.042","DOIUrl":"https://doi.org/10.18773/austprescr.2024.042","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"162-163"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reflections on community antimicrobial use in Australia. 对澳大利亚社区抗菌药使用情况的思考。
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.047
John Turnidge, Carolyn Hullick, Kim Stewart
{"title":"Reflections on community antimicrobial use in Australia.","authors":"John Turnidge, Carolyn Hullick, Kim Stewart","doi":"10.18773/austprescr.2024.047","DOIUrl":"https://doi.org/10.18773/austprescr.2024.047","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"138-139"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune checkpoint inhibitors and immune-related adverse events. 免疫检查点抑制剂与免疫相关不良事件。
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.039
Winston Naidoo, Katharine Cuff, Marissa Ryan
{"title":"Immune checkpoint inhibitors and immune-related adverse events.","authors":"Winston Naidoo, Katharine Cuff, Marissa Ryan","doi":"10.18773/austprescr.2024.039","DOIUrl":"https://doi.org/10.18773/austprescr.2024.039","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"153-155"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clascoterone for acne. 治疗痤疮的 Clascoterone
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.040
{"title":"Clascoterone for acne.","authors":"","doi":"10.18773/austprescr.2024.040","DOIUrl":"https://doi.org/10.18773/austprescr.2024.040","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"160-161"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prasterone for vulvar and vaginal atrophy in postmenopausal women. 普拉雄酮治疗绝经后妇女的外阴和阴道萎缩。
IF 3.4
Australian Prescriber Pub Date : 2024-10-01 DOI: 10.18773/austprescr.2024.041
{"title":"Prasterone for vulvar and vaginal atrophy in postmenopausal women.","authors":"","doi":"10.18773/austprescr.2024.041","DOIUrl":"https://doi.org/10.18773/austprescr.2024.041","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 5","pages":"164"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mineralocorticoid receptor antagonists in adults with resistant hypertension and obstructive sleep apnoea. 矿物质皮质激素受体拮抗剂在成人耐药性高血压和阻塞性睡眠呼吸暂停患者中的应用。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.033
{"title":"Mineralocorticoid receptor antagonists in adults with resistant hypertension and obstructive sleep apnoea.","authors":"","doi":"10.18773/austprescr.2024.033","DOIUrl":"10.18773/austprescr.2024.033","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"129-130"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological management of polycystic ovary syndrome. 多囊卵巢综合征的药物治疗。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.030
Carolyn Ee, Chau Thien Tay
{"title":"Pharmacological management of polycystic ovary syndrome.","authors":"Carolyn Ee, Chau Thien Tay","doi":"10.18773/austprescr.2024.030","DOIUrl":"10.18773/austprescr.2024.030","url":null,"abstract":"<p><p>Polycystic ovary syndrome is a common and frequently undiagnosed female endocrine disorder that is associated with diverse symptoms and features, and an increased risk of long-term chronic diseases such as type 2 diabetes and cardiovascular disease. Pharmacotherapy for polycystic ovary syndrome should be directed at the key concerns of the individual patient. The combined oral contraceptive pill or metformin may be prescribed for irregular periods. The combined oral contraceptive pill is preferred over antiandrogens for treatment of hirsutism and acne. Metformin is of benefit for reducing excess body weight and improving hormonal and metabolic outcomes in those with high metabolic risk (e.g. body mass index greater than 25 kg/m<sup>2</sup>). Inositol appears to have limited benefits for metabolic outcomes, although it is associated with fewer adverse effects than metformin. Modification of lifestyle factors is important as part of a holistic approach to managing polycystic ovary syndrome. Anti-obesity drugs may be considered for weight management in addition to lifestyle interventions.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"109-112"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信